Cited 7 times in
Treatment of Hodgkin's disease: A twenty-year follow-up of patients at a center in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 노재경 | - |
dc.contributor.author | 서창옥 | - |
dc.contributor.author | 정준원 | - |
dc.date.accessioned | 2015-06-10T13:02:43Z | - |
dc.date.available | 2015-06-10T13:02:43Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/110906 | - |
dc.description.abstract | Hodgkin's disease (HD) is a hematologic malignancy which shows common features regardless of race, but racial differences may be considered with certain clinical characteritcs. HD in Korea shows somewhat different characteristics when compared to cases in Western countries. We evaluated the clinical and histopathologic characteristics of HD, the outcomes of various chemotherapy regimens, and prognostic factors of HD in Korea. One hundred and five patients with initial histopathologic diagnosis of Hodgkin's disease were retrospectively reviewed 20 years after diagnosis at Yonsei University College of Medicine. Nodular sclerosis was the most common histopathogic subtype (41%) and mixed cellularity was nearly as common (40%). The overall complete remission rate (CR) was 87.6%. The disease-free survival (DFS) and overall survival (OS) rate were 79.2% and 84.8% at 5-years, 70% and 79.2% at 10- and 20-years. There were no significant differences in CR rate and DFS, but OS rates were significantly higher in m-BACOP and ABVD regimen. Univariate analysis revealed that age, B-symptom, ECOG scale, Ann Arbor stage, international prognostic index, and serum β2-microglobulin level were significant prognostic factors for both DFS and OS. Multivariate analysis demonstrated that age, B symptoms, and ECOG scale were significant prognostic factors for OS only. In conclusion, the survival rates of HD patients in our center were superior to those of previous reports in Korea and Western countries. Considering the higher OS rate and decreased incidence of side effects, the ABVD regimen may be recommended for the initial treatment of Hodgkin's disease. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 455~465 | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Agents/pharmacology* | - |
dc.subject.MESH | Child | - |
dc.subject.MESH | Child, Preschool | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Hodgkin Disease/mortality | - |
dc.subject.MESH | Hodgkin Disease/therapy* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Korea | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Remission Induction | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Treatment of Hodgkin's disease: A twenty-year follow-up of patients at a center in Korea | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학) | - |
dc.contributor.googleauthor | June-Won Cheong | - |
dc.contributor.googleauthor | Soo Young Park | - |
dc.contributor.googleauthor | Jae Kyung Roh | - |
dc.contributor.googleauthor | Chang Ok Suh | - |
dc.contributor.googleauthor | Jee Sook Hahn | - |
dc.identifier.doi | 10.3349/ymj.2006.47.4.455 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01290 | - |
dc.contributor.localId | A01919 | - |
dc.contributor.localId | A03729 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 16941733 | - |
dc.subject.keyword | Hodgkin's disease | - |
dc.subject.keyword | twenty year survival | - |
dc.subject.keyword | chemotherapy | - |
dc.subject.keyword | Korea | - |
dc.contributor.alternativeName | Roh, Jae Kyung | - |
dc.contributor.alternativeName | Suh, Chang Ok | - |
dc.contributor.alternativeName | Cheong, June Won | - |
dc.contributor.affiliatedAuthor | Roh, Jae Kyung | - |
dc.contributor.affiliatedAuthor | Suh, Chang Ok | - |
dc.contributor.affiliatedAuthor | Cheong, June-Won | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 47 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 455 | - |
dc.citation.endPage | 465 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.47(4) : 455-465, 2006 | - |
dc.identifier.rimsid | 55609 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.